Clinical trial
Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible…
NCT03361865 · Incyte Corporation, Industry · Completed
Key facts
| NCT number | NCT03361865 |
|---|---|
| Title | Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307) |
| Official title | A Phase 3 Randomized, Double-Blind Trial of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) or Placebo in Participants With Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307) |
| Lead sponsor | Incyte Corporation, Industry |
| Collaborators | Merck Sharp & Dohme LLC Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | UC (Urothelial Cancer) |
| Intervention type | Drug |
| Interventions | Pembrolizumab, Epacadostat, Placebo |
| Enrollment | 93 |
| Start date | Dec 4, 2017 |
| Primary completion | Aug 9, 2018 |
| Completion | Aug 4, 2020 |
| First posted | Dec 5, 2017 |
| Last update posted | Aug 22, 2025 |
| Countries | Australia, Belgium, Canada, France, Germany, Ireland, Israel, Italy, Japan, Netherlands, Poland, Russia and 6 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: